MENS Key Statistics, Chart & Performance
The current stock price of MENS is 29.2 USD. In the past month the price decreased by -21.97%.
MENS Latest News, Press Relases and Analysis
MENS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About MENS
Company Profile
Jyong Biotech Ltd. operates as a holding company, which engages in the development of biotechnology products. The company is headquartered in Taipei, New Taipei and currently employs 29 full-time employees. The company went IPO on 2025-06-17. The firm is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The firm has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer.
Company Info
JYONG BIOTECH LTD
23F-3, No.95, Section 1, Xintai 5th, Xizhi District
Taipei NEW TAIPEI TW
Employees: 29
Phone: 886227325205
JYONG BIOTECH LTD / MENS FAQ
What does MENS do?
Jyong Biotech Ltd. operates as a holding company, which engages in the development of biotechnology products. The company is headquartered in Taipei, New Taipei and currently employs 29 full-time employees. The company went IPO on 2025-06-17. The firm is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The firm has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer.
What is the stock price of JYONG BIOTECH LTD today?
The current stock price of MENS is 29.2 USD. The price increased by 0.03% in the last trading session.
Does JYONG BIOTECH LTD pay dividends?
MENS does not pay a dividend.
What is the ChartMill rating of JYONG BIOTECH LTD stock?
MENS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists MENS stock?
MENS stock is listed on the Nasdaq exchange.
What is the outstanding short interest for JYONG BIOTECH LTD?
The outstanding short interest for JYONG BIOTECH LTD (MENS) is 0.5% of its float.
MENS Technical Analysis
MENS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MENS. Both the profitability and financial health of MENS have multiple concerns.
MENS Financial Highlights
Over the last trailing twelve months MENS reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS increased by 31.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -47.42% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |